The Center for Immuno-Oncology (CIO) investigates how our immune system reacts to cancer and what we can do to improve tumour immunity. We combine deep fundmental understanding of immunology with preclinical studies to translate new knowledge into clinical trials with the aim of developing new life-saving treatments for a spectrum of cancers.
Oxford’s long history of excellence in immunology is now focused on cancer, and CIO is the hub of the University-wide Oxford Cancer Immuno-Oncology Network (OCION) which links immuno-oncology researchers from multiple disciplines from across the University of Oxford, its affiliated hospitals and industrial partners.
CIO News
£1.7 million for vaccine to prevent lung cancer
2 April 2024
Oxford and UCL researchers seeking to create the world’s first vaccine to prevent lung cancer in people at high risk of the disease have been granted up to £1.7 million from Cancer Research UK and the CRIS Cancer Foundation.
What's new for Oxford Cancer
-
Oxford receives funding to develop a cancer prevention vaccine for Lynch syndrome
10 September 2024
-
Senior Fellowship awarded to Beth Psaila
29 August 2024
-
CRUK funding will help develop new targets for ovarian cancer
21 August 2024
-
Ground-breaking study reveals previously unknown genetic causes of colorectal cancer
7 August 2024
-
UK’s most ambitious melanoma research study created for patients, by patients
6 August 2024